Skip to main content

Bumper Listing: Chemcon Speciality Chemicals debuts at Rs 730.95, a 115% premium

Chemcon enjoys high entry barriers which leads to client stickiness and long standing relationships, said Motilal Oswal.

Chemcon Speciality Chemicals, which earns around 65 percent revenue from the pharmaceutical industry, opened with a bumper 115 percent premium over issue price on October 1.

The stock listed at Rs 730.95 per shares on the BSE, against its issue price of Rs 340 per share, meeting analysts' expectations.

On the National Stock Exchange, it started off the inning at Rs 731, a 115 percent premium.

After strong opening, Chemcon witnessed some profit booking at higher levels despite strong market trend, which could be due to high valuations.

At 10:02 hours IST, Chemcon was trading at Rs 614, up by Rs 274 or 80.59 percent over issue price, with volume of 4.17 lakh shares, but was down 16 percent from opening price on the BSE.

On the NSE, it was quoting at Rs 619, up 82 percent, with volumes of

21,08,512 shares, but it was down 15.3 percent from opening price.

Chemcon Speciality Chemicals with a small issue size of Rs 318 crore has seen stellar response from all categories of investors and was subscribed 149.3 times during September 21-23. Hence the listing premium seems to be clearly justified the demand witnessed during subscription.

It is the speciality chemicals manufacturer of pharma chemicals (HMDS, CMIC) and oilwell completion chemicals (inorganic bromides).

It is the only manufacturer of HMDS in India and 3rd largest globally. It is also the largest player of CMIC in India and 2nd largest worldwide. Additionally, Chemcon is the only manufacturer of zinc bromide and the largest of calcium bromide in India.

"We see Chemcon is well-positioned to substitute the imports from China and has an opportunity to grow and double its revenue as well as profits in 3-4 years. If we look at specialized chemicals as a sector it is been re-rated in last 3-6 month due to ongoing saga with Chinese but the concern remains on procurement of raw materials from China which accounts around 20 percent to its total expenditure," Prashanth Tapse, AVP Research at Mehta Equities told Moneycontrol.

Company's 40 percent of the revenues come from export which has grown at a CAGR of 18 percent over FY18-20.

Chemcon enjoys high entry barriers which leads to client stickiness and long standing relationships, said Motilal Oswal.

During FY18-20, Chemcon's revenue/EBITDA/PAT grew at a CAGR of 29/25/36 percent, led by volume and price growth.

Its EBITDA margins are strong at 26.8 percent in FY20 given the leadership position and high complex nature products. Given continuous capex incurred over the last three years, the return ratios have tapered down, though healthy with ROE/ROCE at 40/33 percent in FY20, the brokerage said.

The maiden public issue comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters.

Chemcon plans to set up two more plants for manufacture of Pharma Chemicals (capex of Rs 41 crore), which would increase its capacity from 375KL to 626KL (operational by FY22-end). This will help Chemcon expand its reach in India which is currently net importer of HMDS/ CMIC.

Chemcon also aims to expand its product portfolio and usage of its existing products to other industries.

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more